PriceTargets.com logo

DocGo - DCGO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.10
  • Forecasted Upside: 35.25%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$4.51 As of 12/20/2024 06:40 PM ET
▲ +0.16 (3.68%)

This chart shows the closing price for DCGO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DocGo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCGO

Analyst Price Target is $6.10
▲ +35.25% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for DocGo in the last 3 months. The average price target is $6.10, with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 35.25% upside from the last price of $4.51.

This chart shows the closing price for DCGO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in DocGo. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$5.00 ➝ $5.00
8/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$5.00 ➝ $5.00
8/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
5/9/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$9.00 ➝ $5.00
5/9/2024BTIG ResearchLower TargetBuy ➝ Buy$11.00 ➝ $7.00
5/9/2024Needham & Company LLCLower TargetBuy ➝ Buy$10.00 ➝ $7.00
5/9/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$11.00 ➝ $5.00
4/30/2024Stifel NicolausLower TargetBuy ➝ Buy$8.00 ➝ $6.50
4/11/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$10.00 ➝ $9.00
4/10/2024Stifel NicolausLower TargetBuy ➝ Buy$11.00 ➝ $8.00
4/10/2024BTIG ResearchLower TargetBuy ➝ Buy$13.00 ➝ $11.00
2/29/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$13.00 ➝ $11.00
2/29/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$11.00 ➝ $10.00
2/29/2024Needham & Company LLCLower TargetBuy ➝ Buy$14.00 ➝ $10.00
2/23/2024Stifel NicolausLower TargetBuy ➝ Buy$12.00 ➝ $11.00
11/27/2023Stifel NicolausReiterated RatingBuy ➝ Buy$12.00
10/2/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$13.00
9/19/2023BTIG ResearchLower TargetBuy ➝ Buy$15.00 ➝ $13.00
9/18/2023Stifel NicolausReiterated RatingBuy ➝ Buy$12.00
9/18/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$14.00
9/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$13.00
9/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$14.00
8/22/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$14.00
8/18/2023BTIG ResearchInitiated CoverageBuy$15.00
8/8/2023Northland SecuritiesBoost Target$15.00 ➝ $16.00
8/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$14.00
7/31/2023Stifel NicolausReiterated RatingBuy ➝ Buy$12.00
4/21/2023Needham & Company LLCReiterated RatingBuy$14.00
4/20/2023Cantor FitzgeraldInitiated CoverageOverweight$11.00
3/14/2023Needham & Company LLCReiterated RatingBuy$14.00
5/18/2022Needham & Company LLCReiterated RatingBuy$14.00
5/11/2022Canaccord Genuity GroupLower Target$13.00 ➝ $10.00
4/19/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$11.00
3/16/2022Needham & Company LLCReiterated RatingBuy$14.00
1/19/2022Stifel NicolausInitiated CoverageBuy$14.00
12/7/2021Needham & Company LLCInitiated CoverageBuy$14.00
11/30/2021Northland SecuritiesBoost TargetOutperform$16.00 ➝ $22.00
11/30/2021BarclaysInitiated CoverageOverweight$14.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 8 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

DocGo logo
DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.
Read More

Today's Range

Now: $4.51
Low: $4.24
High: $4.64

50 Day Range

MA: $3.92
Low: $3.20
High: $4.51

52 Week Range

Now: $4.51
Low: $2.75
High: $5.70

Volume

1,387,373 shs

Average Volume

492,184 shs

Market Capitalization

$460.25 million

P/E Ratio

16.11

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of DocGo?

The following Wall Street analysts have issued stock ratings on DocGo in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Cantor Fitzgerald, Needham & Company LLC, and Stifel Nicolaus.
View the latest analyst ratings for DCGO.

What is the current price target for DocGo?

0 Wall Street analysts have set twelve-month price targets for DocGo in the last year. Their average twelve-month price target is $6.10, suggesting a possible upside of 35.3%. BTIG Research has the highest price target set, predicting DCGO will reach $7.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $5.00 for DocGo in the next year.
View the latest price targets for DCGO.

What is the current consensus analyst rating for DocGo?

DocGo currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DCGO will outperform the market and that investors should add to their positions of DocGo.
View the latest ratings for DCGO.

What other companies compete with DocGo?

Other companies that are similar to DocGo include Fortrea, Viridian Therapeutics, AdaptHealth, CareDx and The Pennant Group. Learn More about companies similar to DocGo.

How do I contact DocGo's investor relations team?

The company's listed phone number is 844-443-6246 and its investor relations email address is [email protected]. The official website for DocGo is www.docgo.com. Learn More about contacing DocGo investor relations.